US20170258748A1 - Oral pharmaceutical composition of isotretinoin - Google Patents
Oral pharmaceutical composition of isotretinoin Download PDFInfo
- Publication number
- US20170258748A1 US20170258748A1 US15/603,741 US201715603741A US2017258748A1 US 20170258748 A1 US20170258748 A1 US 20170258748A1 US 201715603741 A US201715603741 A US 201715603741A US 2017258748 A1 US2017258748 A1 US 2017258748A1
- Authority
- US
- United States
- Prior art keywords
- isotretinoin
- less
- pharmaceutical composition
- oral pharmaceutical
- dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005280 isotretinoin Drugs 0.000 title claims abstract description 76
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims abstract description 27
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical group OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title claims abstract 8
- 230000009246 food effect Effects 0.000 claims abstract description 13
- 235000021471 food effect Nutrition 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 57
- 239000006185 dispersion Substances 0.000 claims description 28
- 239000002775 capsule Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical group OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 69
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 33
- 239000002245 particle Substances 0.000 description 21
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 16
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 239000008389 polyethoxylated castor oil Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229920000136 polysorbate Polymers 0.000 description 11
- 239000000473 propyl gallate Substances 0.000 description 9
- 235000010388 propyl gallate Nutrition 0.000 description 9
- 229940075579 propyl gallate Drugs 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 7
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000020937 fasting conditions Nutrition 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 229910052726 zirconium Inorganic materials 0.000 description 5
- -1 i.e. Chemical compound 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010049141 Acne fulminans Diseases 0.000 description 1
- 206010057254 Connective tissue inflammation Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940059473 absorica Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940080498 isotretinoin 40 mg Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the present invention provides an oral pharmaceutical composition of isotretinoin with a reduced food effect.
- the present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
- Isotretinoin is a retinoid (also known as 13-cis retinoic acid). Owing to its low water solubility, the oral bioavailability of isotretinoin is low.
- PCT Publication No. WO 00/25772 discloses that the presently marketed formulation of isotretinoin, i.e., Accutane®, contains isotretinoin at a mean particle size of about 100 ⁇ m resulting in only 20% oral bioavailability. Therefore, this application discloses a formulation of isotretinoin having a reduced particle size, thereby enhancing the oral bioavailability.
- U.S. Pat. Nos. 7,435,427 and 8,367,102 cover the marketed formulation of Absorica .
- These patents disclose capsules comprising a semi-solid suspension of isotretinoin containing at least two lipidic excipients, one having an HLB value equal to or greater than 10 and the other being an oily vehicle.
- These patents are based on the use of the “Lidose technology” to provide a formulation of isotretinoin with enhanced bioavailability.
- the oral bioavailability of a drug is affected by various factors, which include aqueous solubility, absorption of drug through gastrointestinal tract, first pass effect, or food effect.
- the “food effect” as used herein means food-drug interactions which either decrease or increase the extent of drug absorption.
- Isotretinoin is known to have a food effect, i.e., its absorption is dependent on the presence of the food in the stomach. Therefore, there is a need to develop a composition of isotretinoin which exhibits a reduced food effect.
- the present invention provides an oral pharmaceutical composition comprising isotretinoin wherein said composition exhibits a reduced food effect.
- the present invention further provides an oral pharmaceutical composition comprising:
- the present composition is in the form of a dispersion which is further filled into capsules.
- the present invention further provides a process for preparing the oral pharmaceutical composition of the present invention. It also provides a method of treating acne by administering the oral pharmaceutical composition of the present invention.
- the present invention provides an oral pharmaceutical composition comprising isotretinoin wherein said composition exhibits a reduced food effect.
- said composition exhibits reduced food effect in comparison to the marketed EpurisTM capsules as indicated by higher C max and AUC in fasting state.
- said composition exhibits a mean C max under fasting condition which is about 1.9 times higher than the C max of EpurisTM capsules.
- said composition exhibits a mean AUC under fasting condition which is about 1.7 times higher than the AUC of EpurisTM capsules.
- the composition when administered orally, has a mean fed/fasted ratio of AUC of about 1.26 and a mean fed/fasted ratio of C max of about 1.10.
- the present invention provides an oral pharmaceutical composition comprising:
- said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
- said composition comprises isotretinoin in an amount of about 40 mg.
- said composition comprises isotretinoin in an amount of about 36 mg.
- said composition comprises isotretinoin in an amount of about 32 mg.
- said composition comprises isotretinoin in an amount of about 16 mg.
- said surfactants include, but are not limited to, polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters such as polyoxyethylethylene monostearate, polyoxyethylene monolaurate, and polyoxyethylene monooleate; polyethoxylated castor oils (e.g., Cremophor® EL 35); polyethylene glycol glycerides (e.g., Gelucire® 44/14); vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof.
- polysorbates prepared from lauric, palmitic, stearic, and oleic acid
- polyoxyethylene monoesters such as polyoxyethylethylene monostearate, polyoxyethylene monolaurate, and polyoxyethylene monooleate
- polyethoxylated castor oils e.g., Cremophor® EL 35
- the surfactant is present in an amount of about 1% w/w to about 99% w/w by total weight of the composition; preferably in an amount of about 10% w/w to about 80% w/w by total weight of the composition; more preferably in an amount of about 30% w/w to about 80% w/w by total weight of the composition.
- said co-solvents include, but are not limited to, propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric/caprylic glyceride, and mixtures thereof.
- composition further comprises an antioxidant.
- the antioxidant includes, but is not limited to, butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.
- the oral pharmaceutical composition is in the form of a dispersion which is further filled into capsules.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 90 is less than 60 ⁇ m, less than 55 ⁇ m, less than 50 ⁇ m, less than 45 ⁇ m, less than 40 ⁇ m, less than 35 ⁇ m, less than 30 ⁇ m, less than 25 ⁇ m, less than 20 ⁇ m, less than 15 ⁇ m, or less than 10 ⁇ m.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 90 is less than 30 ⁇ m.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 50 is less than 40 ⁇ m, less than 35 ⁇ m, less than 30 ⁇ m, less than 25 ⁇ m, less than 20 ⁇ m, less than 15 ⁇ m, or less than 10 ⁇ m or less than 5 ⁇ m.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 50 is less than 15 ⁇ m.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 10 is less than 20 ⁇ m, less than 18 ⁇ m, less than 17 ⁇ m, less than 15 ⁇ m, less than 12 ⁇ m, less than 10 ⁇ m, less than 8 ⁇ m, less than 7 ⁇ m, less than 5 ⁇ m, or less than 2 ⁇ m.
- the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 10 is less than 7 ⁇ m.
- the oral pharmaceutical composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 90 is less than 60 ⁇ m and D 50 is less than 40 ⁇ m.
- the oral pharmaceutical composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D 90 is less than 60 ⁇ m, D 50 is less than 40 ⁇ m, and D 10 is less than 20 ⁇ m.
- said oral pharmaceutical composition is stable when stored at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months or to the extent necessary for the use of the composition.
- step (b) dispersing isotretinoin into the solution of step (a);
- step (c) milling the dispersion of step (b) in a milling apparatus
- step (d) filling the milled dispersion of step (d) into a capsule.
- an antioxidant is added in step (a) of the process.
- the present invention provides a method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
- the present invention provides a method of treating acne by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
- isotretinoin refers to isotretinoin in its crystalline or amorphous form, its esters, salts, or derivatives thereof.
- stable refers to chemical stability, wherein not more than 1.5% w/w of total related substances are formed on storage at accelerated conditions of stability at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months or to the extent necessary for use of the composition.
- AUC refers to the area under the time/plasma concentration curve after administration of the pharmaceutical composition.
- AUC 0-infinity denotes the area under the plasma concentration versus time curve from time 0 to infinity;
- AUC 0-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
- C max refers to the maximum concentration of isotretinoin in the blood following administration of the pharmaceutical composition.
- t max refers to the time in hours when C max is achieved following administration of the pharmaceutical composition.
- food effect means food-drug interactions which either decrease or increase the extent of drug absorption. It refers to a relative difference in AUC, C max and/or t max of a drug, when said drug or a formulation thereof is administered orally to a human concomitantly with food or in a fed state as compared to the same values when the same formulation is administered in a fasted state or without food.
- D 10 refers to the particle size of isotretinoin where 10% (w/v) of the particles have a size less than the defined D 10 value
- D 50 refers to the particle size of isotretinoin where 50% (w/v) of the particles have a size less than the defined D 50 value
- D 90 refers to the particle size of isotretinoin where 90% (w/v) of the particles have a size less than the defined D 90 value.
- Defined D 10 value/D 50 value/D 90 value refers to the values defined in the embodiments.
- substantially free of oil includes the complete absence of oil and the presence of less than 5% of oil.
- the size reduction of isotretinoin is achieved by wet milling the dispersion of isotretinoin in an oily vehicle or the dispersion of isotretinoin in an aqueous medium using mechanical means such as a ball mill, and media mills such as a sand mill, DYNO®-mill, or a bead mill.
- the grinding media in these mills can comprise spherical particles such as stainless steel beads or zirconium oxide balls.
- Example 2 The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg EpurisTM capsules) for the release profile in the FDA recommended dissolution medium as given below:
- Dissolution Media 0.05M buffer pH 7.8 with 0.5% w/v N,N- dimethyl dodecylamine N-oxide Apparatus/RPM/Vol USP Type I (20 mesh basket)/100/900 mL % of Drug Released in time (minutes) Sample 15 30 45 60 90 120 180 Test 84 94 94 94 95 97 98 Reference 1 9 24 49 89 100 100
- test product has a better dissolution profile in comparison to the reference product.
- Example 2 The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg EpurisTM capsules) under fed conditions on 18 healthy adult male subjects, out of these, 15 subjects completed all the three periods of the study.
- Example 2 The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg EpurisTM capsules) under fasting conditions in 18 healthy adult male subjects, out of these 14 subjects completed all the three periods of the study.
- Test has shown 1.9-fold higher C max and 1.7-fold higher AUC as compared to Reference under fasting condition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
Description
- The present invention provides an oral pharmaceutical composition of isotretinoin with a reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
- Isotretinoin is a retinoid (also known as 13-cis retinoic acid). Owing to its low water solubility, the oral bioavailability of isotretinoin is low. PCT Publication No. WO 00/25772 discloses that the presently marketed formulation of isotretinoin, i.e., Accutane®, contains isotretinoin at a mean particle size of about 100 μm resulting in only 20% oral bioavailability. Therefore, this application discloses a formulation of isotretinoin having a reduced particle size, thereby enhancing the oral bioavailability.
- U.S. Pat. Nos. 7,435,427 and 8,367,102 cover the marketed formulation of Absorica . These patents disclose capsules comprising a semi-solid suspension of isotretinoin containing at least two lipidic excipients, one having an HLB value equal to or greater than 10 and the other being an oily vehicle. These patents are based on the use of the “Lidose technology” to provide a formulation of isotretinoin with enhanced bioavailability.
- The oral bioavailability of a drug is affected by various factors, which include aqueous solubility, absorption of drug through gastrointestinal tract, first pass effect, or food effect. The “food effect” as used herein means food-drug interactions which either decrease or increase the extent of drug absorption. Isotretinoin is known to have a food effect, i.e., its absorption is dependent on the presence of the food in the stomach. Therefore, there is a need to develop a composition of isotretinoin which exhibits a reduced food effect.
- The present invention provides an oral pharmaceutical composition comprising isotretinoin wherein said composition exhibits a reduced food effect. The present invention further provides an oral pharmaceutical composition comprising:
- a) isotretinoin;
- b) one or more surfactants having HLB value of 10 or greater; and
- c) one or more co-solvents wherein said composition is substantially free of oil.
- The present composition is in the form of a dispersion which is further filled into capsules. The present invention further provides a process for preparing the oral pharmaceutical composition of the present invention. It also provides a method of treating acne by administering the oral pharmaceutical composition of the present invention.
- In one aspect, the present invention provides an oral pharmaceutical composition comprising isotretinoin wherein said composition exhibits a reduced food effect.
- In one embodiment of the above aspect, said composition exhibits reduced food effect in comparison to the marketed Epuris™ capsules as indicated by higher Cmax and AUC in fasting state.
- In another embodiment of the above aspect, said composition exhibits a mean Cmax under fasting condition which is about 1.9 times higher than the Cmax of Epuris™ capsules.
- In another embodiment of the above aspect, said composition exhibits a mean AUC under fasting condition which is about 1.7 times higher than the AUC of Epuris™ capsules.
- In another embodiment of the above aspect, the composition, when administered orally, has a mean fed/fasted ratio of AUC of about 1.26 and a mean fed/fasted ratio of Cmax of about 1.10.
- In another aspect, the present invention provides an oral pharmaceutical composition comprising:
- a) isotretinoin;
- b) one or more surfactants having HLB value of 10 or greater; and
- c) one or more co-solvents wherein said composition is substantially free of oil.
- In one embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 1 mg to 100 mg, 5 mg to 50 mg, 10 mg to 40 mg, 9 mg to 36 mg, or 8 mg to 32 mg.
- In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 40 mg.
- In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 36 mg.
- In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 32 mg.
- In another embodiment of the above aspect, said composition comprises isotretinoin in an amount of about 16 mg.
- In one embodiment of the above aspect, said surfactants include, but are not limited to, polysorbates prepared from lauric, palmitic, stearic, and oleic acid; polyoxyethylene monoesters such as polyoxyethylethylene monostearate, polyoxyethylene monolaurate, and polyoxyethylene monooleate; polyethoxylated castor oils (e.g., Cremophor® EL 35); polyethylene glycol glycerides (e.g., Gelucire® 44/14); vitamin E TPGS; dioctyl sodium sulfosuccinate; sodium lauryl sulfate; poloxamers; and mixtures thereof.
- In another embodiment of the above aspect, the surfactant is present in an amount of about 1% w/w to about 99% w/w by total weight of the composition; preferably in an amount of about 10% w/w to about 80% w/w by total weight of the composition; more preferably in an amount of about 30% w/w to about 80% w/w by total weight of the composition.
- In another embodiment of the above aspect, said co-solvents include, but are not limited to, propylene glycol, polypropylene glycol, polyethylene glycols, diethyleneglycol monoethyl ether, glyceryl caprylate, capric/caprylic glyceride, and mixtures thereof.
- In another embodiment of the above aspect, the composition further comprises an antioxidant.
- The antioxidant includes, but is not limited to, butylated hydroxy anisole, butylated hydroxy toluene, tocopherol, ascorbyl palmitate, ascorbic acid, sodium metabisulfite, sodium sulfite, sodium thiosulfate, propyl gallate, and mixtures thereof.
- In one embodiment of the above aspect, the oral pharmaceutical composition is in the form of a dispersion which is further filled into capsules.
- In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm, less than 55 μm, less than 50 μm, less than 45 μm, less than 40 μm, less than 35 μm, less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm.
- In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 30 μm.
- In another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D50 is less than 40 μm, less than 35 μm, less than 30 μm, less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm or less than 5 μm.
- In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D50 is less than 15 μm.
- In another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D10 is less than 20 μm, less than 18 μm, less than 17 μm, less than 15 μm, less than 12 μm, less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm.
- In yet another embodiment of the above aspect, the composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D10 is less than 7 μm.
- In yet another embodiment of the above aspect, the oral pharmaceutical composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm and D50 is less than 40 μm.
- In yet another embodiment of the above aspect, the oral pharmaceutical composition comprises isotretinoin wherein the particle size distribution of isotretinoin is such that D90 is less than 60 μm, D50 is less than 40 μm, and D10 is less than 20 μm.
- In yet another embodiment, said oral pharmaceutical composition is stable when stored at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months or to the extent necessary for the use of the composition.
- In yet another aspect, there is provided a process for the preparation of an oral pharmaceutical composition wherein the process comprises:
- (a) adding one or more of surfactants in a co-solvent or a mixture of co-solvents;
- (b) dispersing isotretinoin into the solution of step (a);
- (c) milling the dispersion of step (b) in a milling apparatus; and
- (d) filling the milled dispersion of step (d) into a capsule.
- In an embodiment of the above aspect, an antioxidant is added in step (a) of the process.
- In still another aspect, the present invention provides a method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, psoriasis, cutaneous lupus erythematosus, acne fulminans, squamous cell carcinoma, or cutaneous photoaging by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
- In one embodiment of the above aspect, the present invention provides a method of treating acne by administering to the individual in need thereof the oral pharmaceutical composition of the present invention.
- The term “isotretinoin” refers to isotretinoin in its crystalline or amorphous form, its esters, salts, or derivatives thereof.
- The term “stable,” as used herein, refers to chemical stability, wherein not more than 1.5% w/w of total related substances are formed on storage at accelerated conditions of stability at 40° C. and 75% relative humidity or at 25° C. and 60% relative humidity for a period of at least three months or to the extent necessary for use of the composition.
- The term “AUC” refers to the area under the time/plasma concentration curve after administration of the pharmaceutical composition. AUC0-infinity denotes the area under the plasma concentration versus time curve from time 0 to infinity; AUC0-t denotes the area under the plasma concentration versus time curve from time 0 to time t.
- The term “Cmax” refers to the maximum concentration of isotretinoin in the blood following administration of the pharmaceutical composition.
- The term “tmax” refers to the time in hours when Cmax is achieved following administration of the pharmaceutical composition.
- The term “food effect” as used herein means food-drug interactions which either decrease or increase the extent of drug absorption. It refers to a relative difference in AUC, Cmax and/or tmax of a drug, when said drug or a formulation thereof is administered orally to a human concomitantly with food or in a fed state as compared to the same values when the same formulation is administered in a fasted state or without food.
- The term “D10” refers to the particle size of isotretinoin where 10% (w/v) of the particles have a size less than the defined D10 value; “D50” refers to the particle size of isotretinoin where 50% (w/v) of the particles have a size less than the defined D50 value; “D90” refers to the particle size of isotretinoin where 90% (w/v) of the particles have a size less than the defined D90 value.
- “Defined D10 value/D50 value/D90 value” refers to the values defined in the embodiments.
- The term “substantially free of oil” includes the complete absence of oil and the presence of less than 5% of oil.
- The size reduction of isotretinoin is achieved by wet milling the dispersion of isotretinoin in an oily vehicle or the dispersion of isotretinoin in an aqueous medium using mechanical means such as a ball mill, and media mills such as a sand mill, DYNO®-mill, or a bead mill. The grinding media in these mills can comprise spherical particles such as stainless steel beads or zirconium oxide balls.
- The invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
-
-
Ingredients Quantity (% w/w) Isotretinoin 6.61 Cremophor ® EL 35 57.02 Tween ® 80 3.30 Butylated hydroxy toluene 0.09 Propyl gallate 0.05 Propylene glycol 23.96 Vitamin E TPGS 8.92 -
- 1. Cremophor® EL 35, Tween® 80, and propylene glycol were mixed in a stainless steel vessel.
- 2. Butylated hydroxy toluene and propyl gallate were added to the mixture of step 1.
- 3. Isotretinoin was dispersed under stirring into the mixture of step 2.
- 4. The dispersion of step 3 was milled in a Dyno®-Mill containing zirconium beads to achieve a particle size of isotretinoin such that D90 was about 22 μm.
- 5. Vitamin E TPGS was melted at a temperature not exceeding 80° C.
- 6. The milled dispersion of step 4 was heated to below 50° C. under continuous stirring.
- 7. The melted vitamin E TPGS of step 5 was added under stirring to the heated milled dispersion of step 6.
- 8. The dispersion of step 7 was filled into capsules.
-
-
Ingredients Quantity (% w/w) Isotretinoin 5.40 Cremophor ® EL 35 46.62 Tween ® 80 2.70 Butylated hydroxy toluene 0.07 Propyl gallate 0.04 Propylene glycol 19.59 Vitamin E TPGS 7.29 Gelucire ® 44/14 18.24 -
- 1. Cremophor® EL 35, Tween® 80, and propylene glycol were mixed in a stainless steel vessel.
- 2. Butylated hydroxy toluene and propyl gallate were added to the mixture of step 1.
- 3. Isotretinoin was dispersed under stirring into the mixture of step 2.
- 4. The dispersion of step 3 was milled in a Dyno®-Mill containing zirconium beads to achieve a particle size of isotretinoin such that D90 was about 22 μm.
- 5. Vitamin E TPGS was melted at a temperature not exceeding 80° C.
- 6. The milled dispersion of step 4 was heated to below 50° C. with continuous stirring.
- 7. The melted vitamin E TPGS of step 5 was added under stirring to the heated milled dispersion of step 6.
- 8. Gelucire® 44/14 was melted at a temperature not exceeding 80° C. and added under stirring to the dispersion of step 7.
- 9. The dispersion of step 8 was filled into capsules.
- The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg Epuris™ capsules) for the release profile in the FDA recommended dissolution medium as given below:
-
Dissolution Media 0.05M buffer pH 7.8 with 0.5% w/v N,N- dimethyl dodecylamine N-oxide Apparatus/RPM/Vol USP Type I (20 mesh basket)/100/900 mL % of Drug Released in time (minutes) Sample 15 30 45 60 90 120 180 Test 84 94 94 94 95 97 98 Reference 1 9 24 49 89 100 100 - From the above data, it is evident that the test product has a better dissolution profile in comparison to the reference product.
- The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg Epuris™ capsules) under fed conditions on 18 healthy adult male subjects, out of these, 15 subjects completed all the three periods of the study.
- Values for various pharmacokinetic parameters, including observed Cmax, AUC0-t and AUC0-inf were calculated and are provided in Table 1 below.
-
TABLE 1 Comparative pharmacokinetic data for test (T) and reference (R) in 15 healthy adult human male subjects: In Cmax In AUC0-t In AUC0-inf Ratio (T/R) 111.56 106.31 106.67 90% CI 100.31-124.07 101.7-111.12 102.3-111.22 -
- Average tmax values for the Test and Reference were 3.6443 hours and 6.1444 hours, respectively.
- Under fed conditions, the Test prototype showed a comparable behavior to the Reference product (Epuris™) in terms of both rate and extent of absorption. The T/R ratios and 90% CIs for all PK parameters are within the acceptable limits of 80% to 125%.
- The pharmaceutical composition of Example 2 (Test; 40 mg of isotretinoin) was compared with the marketed formulation of isotretinoin (Reference; 40 mg Epuris™ capsules) under fasting conditions in 18 healthy adult male subjects, out of these 14 subjects completed all the three periods of the study.
- Values for various pharmacokinetic parameters, including observed Cmax, AUC0-t and AUC0-inf were calculated and are provided in Table 2 below:
-
TABLE 2 Comparative pharmacokinetic data for Test (T) vs Reference (R) in 14 healthy adult human male subjects: In Cmax In AUC0-t In AUC0-inf Ratio 193.23 179.26 175.24 (T/R) 90% CI 157.56-236.98 156.77-204.98 154.3-199.01 - Test has shown 1.9-fold higher Cmax and 1.7-fold higher AUC as compared to Reference under fasting condition.
- The Effect of Food on the Test Formulation of Example 2 (40 mg Capsules) was also Evaluated and Results are Provided in Table 3 Below:
- Reference (R): Epuris™ 40 mg capsules.
- Test (T): Isotretinoin 40 mg capsules (Example 2).
-
TABLE 3 Relative effect of food (Calculated in number of fold (fed/fasting)) Formulation Cmax AUC0-t Test (T fed/fast) 1.10 1.26 Reference (R fed/fast) 1.95 2.12 -
-
- For Test prototype the AUC under fed condition is approximately 1.26-fold the value observed under fasting condition, whereas Cmax under fed condition is approx. 1.1-fold higher as compared to fasting condition.
- For Epuris™, both AUC and Cmax under fed condition are ˜2-fold higher than under fasted condition.
-
-
Ingredients Quantity (% w/w) Isotretinoin 5.00 Cremophor ® EL 35 37.50 Tween ® 80 4.37 Butylated hydroxy anisole 0.12 Propylene glycol 18.12 Vitamin E TPGS 12.50 Gelucire ® 44/14 22.43 -
- 1. Cremophor® EL 35, Tween® 80, and propylene glycol were mixed in a stainless steel vessel.
- 2. Butylated hydroxy anisole was added to the mixture of step 1.
- 3. Isotretinoin was dispersed under stirring into the mixture of step 2.
- 4. The dispersion of step 3 was milled in a Dyno®-Mill containing zirconium beads to achieve a particle size of isotretinoin such that D90 was about 22 μm.
- 5. Vitamin E TPGS was melted at a temperature not exceeding 80° C.
- 6. The milled dispersion of step 4 was heated to below 50° C. with continuous stirring.
- 7. The melted vitamin E TPGS of step 5 was added under stirring to the heated milled dispersion of step 6.
- 8. Gelucire® 44/14 was melted at a temperature not exceeding 80° C. and added under stirring to the dispersion of step 7.
- 9. The dispersion of step 8 was filled into capsules.
-
-
Ingredients Quantity (% w/w) Isotretinoin 5.40 Cremophor ® EL 35 46.62 Tween ® 80 2.70 Butylated hydroxy toluene 0.07 Propyl gallate 0.04 Propylene glycol 9.795 Polyethylene glycol 9.795 Vitamin E TPGS 7.29 Gelucire ® 44/14 18.24 -
- 1. Cremophor® EL 35, Tween® 80, polyethylene glycol, and propylene glycol were mixed in a stainless steel vessel.
- 2. Butylated hydroxy tolune and propyl gallate were added to the mixture of step 1.
- 3. Isotretinoin was dispersed under stirring into the mixture of step 2.
- 4. The dispersion of step 3 was milled in a Dyno®-Mill containing zirconium beads to achieve a particle size of isotretinoin such that D90 was about 22 μm.
- 5. Vitamin E TPGS was melted at a temperature not exceeding 80° C.
- 6. The milled dispersion of step 4 was heated to below 50° C. with continuous stirring.
- 7. The melted vitamin E TPGS of step 5 was added under stirring to the heated milled dispersion of step 6.
- 8. Gelucire® 44/14 was melted at a temperature not exceeding 80° C. and added under stirring to the dispersion of step 7.
- 9. The dispersion of step 8 was filled into capsules.
-
-
Ingredients Quantity (% w/w) Isotretinoin 5.41 Cremophor ® EL 35 46.63 Tween ® 80 2.70 Butylated hydroxy toluene 0.08 Propyl gallate 0.05 Propylene glycol 9.80 Polyethylene glycol 9.80 Vitamin E TPGS 7.30 Gelucire ® 44/14 18.24 -
- 1. Cremophor® EL 35, Tween® 80, polyethylene glycol, Gelucire® 44/14, vitamin E TPGS, and propylene glycol were mixed in a stainless steel vessel with gentle heating below 50° C.
- 2. Butylated hydroxy tolune and propyl gallate was added to the mixture of step 1.
- 3. Isotretinoin was dispersed under stirring into the mixture of step 2.
- 4. The dispersion of step 3 was milled in a Dyno®-Mill containing zirconium beads to achieve a particle size of isotretinoin such that D90 was about 10 μm.
- 5. The dispersion of step 4 was filled into capsules.
Claims (10)
1-33. (canceled)
34. An oral pharmaceutical composition comprising a micronized isotretinoin having d90 value of not more than 30 microns, wherein said composition is in the form of dispersion in a liquid vehicle and exhibits a reduced food effect.
35. The oral pharmaceutical composition according to claim 34 , wherein said composition comprises a low dose isotretinoin in an amount of about 36 mg, about 32 mg, about 28 mg, about 24 mg, about 20 mg, about 16 mg, or about 8 mg.
36. The oral pharmaceutical composition according to claim 34 , wherein said composition is further filled into capsules.
37. The oral pharmaceutical composition according to claim 34 , wherein the micronized isotretinoin has D90 less than 25 μm, less than 20 μm, less than 15 μm, or less than 10 μm.
38. The oral pharmaceutical composition according to claim 34 , wherein the micronized isotretinoin further has D50 is less than 20 μm, less than 15 μm, less than 10 μm, or less than 5 μm.
39. The oral pharmaceutical composition according to claim 34 , wherein the micronized isotretinoin further has D10 is less than 10 μm, less than 8 μm, less than 7 μm, less than 5 μm, or less than 2 μm.
40. The oral pharmaceutical composition according to claim 34 , wherein the composition releases more than 50% of isotretinoin in 15 minutes in a 900 ml of media with a pH of 7.8 rotating at a 100 rpm in USP Type I apparatus.
41. An oral pharmaceutical composition according to claim 34 wherein the composition has a mean fed/fasted ratio of Cmax of about 1.10.
42. An oral pharmaceutical composition according to claim 34 wherein the has a mean fed/fasted ratio of AUC0-t of about 1.26.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/603,741 US20170258748A1 (en) | 2014-07-31 | 2017-05-24 | Oral pharmaceutical composition of isotretinoin |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2158DE2014 | 2014-07-31 | ||
IN2158/DEL/2014 | 2014-07-31 | ||
PCT/IB2015/054101 WO2016016742A1 (en) | 2014-07-31 | 2015-05-29 | Oral pharmaceutical composition of isotretinoin |
US14/958,398 US9700535B2 (en) | 2014-07-31 | 2015-12-03 | Oral pharmaceutical composition of isotretinoin |
US15/603,741 US20170258748A1 (en) | 2014-07-31 | 2017-05-24 | Oral pharmaceutical composition of isotretinoin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/958,398 Continuation US9700535B2 (en) | 2014-07-31 | 2015-12-03 | Oral pharmaceutical composition of isotretinoin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170258748A1 true US20170258748A1 (en) | 2017-09-14 |
Family
ID=55216820
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/958,398 Active 2035-08-04 US9700535B2 (en) | 2014-07-31 | 2015-12-03 | Oral pharmaceutical composition of isotretinoin |
US15/603,741 Abandoned US20170258748A1 (en) | 2014-07-31 | 2017-05-24 | Oral pharmaceutical composition of isotretinoin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/958,398 Active 2035-08-04 US9700535B2 (en) | 2014-07-31 | 2015-12-03 | Oral pharmaceutical composition of isotretinoin |
Country Status (11)
Country | Link |
---|---|
US (2) | US9700535B2 (en) |
EP (1) | EP3174601A4 (en) |
JP (1) | JP2017521470A (en) |
AU (1) | AU2015294993A1 (en) |
BR (1) | BR112017001963A2 (en) |
CA (1) | CA2956831A1 (en) |
MA (1) | MA40447A (en) |
MX (1) | MX2017001331A (en) |
RU (1) | RU2017106013A (en) |
WO (1) | WO2016016742A1 (en) |
ZA (1) | ZA201700843B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517846B2 (en) | 2016-05-26 | 2019-12-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for treating acne |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
EP4236915A1 (en) * | 2020-11-01 | 2023-09-06 | Idrs Labs Pvt Ltd | Oral liquid pharmaceutical compositions of isotretinoin |
WO2024006748A1 (en) | 2022-07-01 | 2024-01-04 | Acrotech Biopharma Inc. | Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
PE20001227A1 (en) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | PROCESSES TO PRODUCE AN ISOTRETINOIN COMPOSITION |
PT1318791E (en) | 2000-09-22 | 2004-11-30 | Galephar M F | ISOTRETINOIN SEMI-SOLID PHARMACEUTICAL COMPOSITION |
BR0117191A (en) * | 2001-12-06 | 2005-05-10 | Ranbaxy Lab Ltd | Isotretinoin nanoparticulate compositions |
SE0303135D0 (en) * | 2003-11-25 | 2003-11-25 | Lipocore Holding Ab | Controlled food effect composition |
EP2143421A1 (en) * | 2008-07-07 | 2010-01-13 | Almirall Hermal GmbH | Topical composition for the treatment of actinic keratosis |
US20120259013A1 (en) * | 2009-05-20 | 2012-10-11 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
US10028972B2 (en) * | 2010-10-21 | 2018-07-24 | Cadila Healthcare Limited | Pharmaceutical compositions of anti-acne agents |
US9078925B2 (en) * | 2012-06-18 | 2015-07-14 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
WO2015181802A2 (en) * | 2014-05-29 | 2015-12-03 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
MA40781A (en) * | 2014-10-01 | 2017-08-08 | Sun Pharmaceutical Ind Ltd | PHARMACEUTICAL COMPOSITION OF LOW DOSAGE ISOTRETINOIN FOR ORAL USE |
CA2987177A1 (en) * | 2015-05-25 | 2016-12-01 | Sun Pharmaceutical Industries Limited | Once-daily oral pharmaceutical composition of isotretinoin |
-
2015
- 2015-05-29 JP JP2017504680A patent/JP2017521470A/en active Pending
- 2015-05-29 CA CA2956831A patent/CA2956831A1/en not_active Abandoned
- 2015-05-29 AU AU2015294993A patent/AU2015294993A1/en not_active Abandoned
- 2015-05-29 EP EP15827289.8A patent/EP3174601A4/en not_active Withdrawn
- 2015-05-29 MA MA040447A patent/MA40447A/en unknown
- 2015-05-29 RU RU2017106013A patent/RU2017106013A/en not_active Application Discontinuation
- 2015-05-29 BR BR112017001963A patent/BR112017001963A2/en not_active IP Right Cessation
- 2015-05-29 WO PCT/IB2015/054101 patent/WO2016016742A1/en active Application Filing
- 2015-05-29 MX MX2017001331A patent/MX2017001331A/en unknown
- 2015-12-03 US US14/958,398 patent/US9700535B2/en active Active
-
2017
- 2017-02-02 ZA ZA2017/00843A patent/ZA201700843B/en unknown
- 2017-05-24 US US15/603,741 patent/US20170258748A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
WO 2005/051354 WO A1 no * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517846B2 (en) | 2016-05-26 | 2019-12-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for treating acne |
Also Published As
Publication number | Publication date |
---|---|
ZA201700843B (en) | 2018-04-25 |
WO2016016742A1 (en) | 2016-02-04 |
MX2017001331A (en) | 2017-05-23 |
EP3174601A1 (en) | 2017-06-07 |
EP3174601A4 (en) | 2018-01-10 |
JP2017521470A (en) | 2017-08-03 |
MA40447A (en) | 2016-02-04 |
US20160081964A1 (en) | 2016-03-24 |
RU2017106013A (en) | 2018-08-28 |
CA2956831A1 (en) | 2016-02-04 |
AU2015294993A1 (en) | 2017-02-16 |
BR112017001963A2 (en) | 2017-11-21 |
US9700535B2 (en) | 2017-07-11 |
RU2017106013A3 (en) | 2018-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2963206C (en) | Oily suspensions of microparticulate isotretinoin with improved oral bioavailability | |
US9700535B2 (en) | Oral pharmaceutical composition of isotretinoin | |
US20130122051A1 (en) | Methods of preparing progesterone pharmaceutical compositions | |
US20170326092A1 (en) | Oral pharmaceutical composition of isotretinoin | |
US20180193299A1 (en) | Oral pharmaceutical composition of isotretinoin | |
US9655849B2 (en) | Solid particulate compositions comprising coenzyme Q10 | |
CN105188670A (en) | Emulsion formulations | |
JP2014098048A5 (en) | ||
US9750711B2 (en) | Low dose oral pharmaceutical composition of isotretinoin | |
CA3083555A1 (en) | Pharmaceutical formulation of 3.alpha.-ethynyl-3.beta.-hydroxyandrostan-17-one oxime | |
CN108498455B (en) | Oily water-soluble medicine nanocrystal and preparation method thereof | |
WO2022116987A1 (en) | Self-microemulsion composition of axitinib | |
CN113546044A (en) | Lurasidone self-microemulsion composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUN PHARMACEUTICAL INDUSTRIES LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAO, RAJESH;FANDA, ANUJ KUMAR;JAIN, SATISH KUMAR;AND OTHERS;SIGNING DATES FROM 20150616 TO 20150618;REEL/FRAME:042822/0658 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |